Valion Bio, Inc. (VBIO)
2.50
-0.27
(-9.75%)
USD |
NASDAQ |
Sep 08, 16:00
2.45
-0.05
(-2.00%)
Pre-Market: 09:13
Valion Bio Shareholders Equity (Quarterly) : 11.88M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 11.88M |
| March 31, 2026 | 18.55M |
| December 31, 2025 | |
| September 30, 2025 | 5.591M |
| June 30, 2025 | 3.687M |
| March 31, 2025 | 3.036M |
| December 31, 2024 | 2.535M |
| September 30, 2024 | 2.834M |
| June 30, 2024 | 4.192M |
| March 31, 2024 | 2.153M |
| December 31, 2023 | 3.58M |
| September 30, 2023 | 5.765M |
| Date | Value |
|---|---|
| June 30, 2023 | 3.161M |
| March 31, 2023 | 5.205M |
| December 31, 2022 | 3.63M |
| September 30, 2022 | 5.772M |
| June 30, 2022 | 8.187M |
| March 31, 2022 | 11.09M |
| December 31, 2021 | 13.27M |
| September 30, 2021 | -5.792M |
| June 30, 2021 | -3.603M |
| March 31, 2021 | 13.27M |
| December 31, 2020 | -1.177M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Outlook Therapeutics, Inc. | -10.39M |
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
| Anika Therapeutics, Inc. | 137.28M |
| BioCryst Pharmaceuticals, Inc. | -454.29M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 32.47M |
| Total Liabilities (Quarterly) | 20.59M |
| Debt to Equity Ratio | 1.465 |
| Current Ratio | 1.110 |
| Net Debt Paydown Yield | -161.3% |